Thermo Fisher Scientific Inc. $TMO Stock Holdings Lessened by SOA Wealth Advisors LLC.

SOA Wealth Advisors LLC. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 23.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 785 shares of the medical research company’s stock after selling 244 shares during the quarter. SOA Wealth Advisors LLC.’s holdings in Thermo Fisher Scientific were worth $318,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. RFG Advisory LLC increased its holdings in shares of Thermo Fisher Scientific by 35.2% in the 1st quarter. RFG Advisory LLC now owns 4,735 shares of the medical research company’s stock worth $2,356,000 after acquiring an additional 1,233 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 35.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,354 shares of the medical research company’s stock worth $3,162,000 after acquiring an additional 1,658 shares during the period. Finally, Apella Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 10.5% in the 1st quarter. Apella Capital LLC now owns 600 shares of the medical research company’s stock worth $272,000 after acquiring an additional 57 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. HSBC reissued a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays raised their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research note on Thursday. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research note on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $585.37.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $525.07 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market cap of $198.27 billion, a P/E ratio of 30.37, a P/E/G ratio of 2.88 and a beta of 0.77. The firm has a 50 day simple moving average of $481.27 and a 200 day simple moving average of $447.60. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $611.49.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.